CytoDyn Registers 376 Million Shares for Resale, Enabling Significant Dilution from Recent Financing
CYDY sits 18% above its 52-week low of $0.193 on elevated volume (2.2× avg).
Summary
CytoDyn Inc. filed a prospectus supplement to register approximately 376 million shares of common stock and shares underlying warrants for resale by selling stockholders, formalizing the potential dilution from its recently completed $18.8 million financing.
Key Events · Financing and Capital Events · CYDY
-
Resale Registration Filed
CytoDyn registered approximately 376 million shares of common stock and shares underlying warrants for resale by selling stockholders.
-
Significant Potential Dilution
The registered shares represent a potential dilution of nearly 30% of the company's current outstanding shares, creating a substantial market overhang.
-
Follows Recent Financing
This registration enables the resale of shares issued in the recently completed $18.8 million financing, which was disclosed in an 8-K on March 5, 2026.
-
Financing Terms Detailed
The financing involved units of common stock and warrants priced at $0.2153 per unit, a discount to the current market price, with warrants exercisable at $0.26.
Analysis · CYDY · Life Sciences
This 424B3 filing formalizes the ability for investors in CytoDyn's recent $18.8 million financing to resell their shares and shares underlying warrants. The financing, which included common stock and warrants at a deep discount, was critical for the company given its going concern warning and liquidity issues. However, the registration of approximately 376 million shares for resale represents a substantial potential dilution of nearly 30% of the company's current outstanding shares. This creates a significant overhang on the stock, as selling stockholders may liquidate their positions, putting downward pressure on the share price. This filing follows the 8-K on March 5, 2026, which disclosed the completion of the financing.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 35.8% of the 1706 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.10%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CYDY was trading at $0.23 on OTC in the Life Sciences sector, with a market capitalization of approximately $288.5M. The 52-week trading range was $0.19 to $0.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.